Clinical data | |
---|---|
Trade names | Cafcit, Gencebok, Cafnea, others |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | By mouth, intravenous (IV) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.125.472 |
Chemical and physical data | |
Formula | C14H18N4O9 |
Molar mass | 386.317 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Caffeine citrate, sold under the brand name Cafcit among others, is a medication used to treat a lack of breathing in premature babies.[5] Specifically it is given to babies who are born at less than 35 weeks or weigh less than 2 kilograms (4.4 lb) once other causes are ruled out.[6] It is given by mouth or slow injection into a vein.[5]
Side effects can include problems feeding, increased heart rate, low blood sugar, necrotizing enterocolitis, and kidney problems.[5][6] Testing blood caffeine levels is occasionally recommended.[5] Although it is often referred to as a citric acid salt of caffeine,[7] as implied by its name, caffeine citrate in fact consists of cocrystals of the two components.[8] Caffeine citrate is in the xanthine family of medication.[6] It works by stimulating the respiratory centers in the brain.[5]
Caffeine was discovered in 1819.[9] It is on the World Health Organization's List of Essential Medicines.[10] The intravenous form may also be taken by mouth.[11]
In June 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of Gencebok.[12] It was approved for use in the European Union in August 2020.[3]
Smit_2015
was invoked but never defined (see the help page).